

Published in final edited form as:

Acad Emerg Med. 2015 January ; 22(1): 94–112. doi:10.1111/acem.12538.

Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions:

A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group

Sean P. Collins, MD, MSc, Alan B. Storrow, MD, Phillip D. Levy, MD, MPH, Nancy Albert, PhD, Javed Butler, MD, Justin A. Ezekowitz, MD, G. Michael Felker, MD, Gregory J. Fermann, MD, Gregg C. Fonarow, MD, Michael M. Givertz, MD, Brian Hiestand, MD, MPH, Judd E. Hollander, MD, David E. Lanfear, MD, Peter S. Pang, MD, MSc, W. Frank Peacock, MD, Douglas B. Sawyer, MD, PhD, John R. Teerlink, MD, and Daniel J. Lenihan, MD

Department of Emergency Medicine, Vanderbilt University, Nashville Veterans Affairs Medical Center (SPC, ABS, DBS), Nashville, TN; the Department of Emergency Medicine, Wayne State University (PDL), Detroit, MI; the Department of Emergency Medicine, University of Cincinnati

© 2015 by the Society for Academic Emergency Medicine

Address for correspondence and reprints: Sean P. Collins, MD, MSc; sean.collins@vanderbilt.edu.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The authors have no relevant financial information to disclose.

DISCLOSURES

SC—Research support from NIH/NHLBI, Medtronic, Cardiorentis, Abbott Point-of-Care, Novartis, The Medicines Company, Astellas, Intersection Medical, and Radiometer; consultant for Trevena, Novartis, Otsuka, Radiometer, The Medicines Company, Medtronic, BRAHMS, Insys, Intersection Medical, and Cardioxyl.

ABS—Current or recent grant support from Abbott Diagnostics, Centers for Medicaid and Medicare Services (CMS), NIH/NHLBI (K12HL1090), UL1TR000445 National Center for Advancing Translational Sciences, and Roche Diagnostics; current consultant for Roche Diagnostics, Novartis Pharmaceuticals Corp., Alere Diagnostics, Trevena, and Beckman Coulter.

NA—none.

JB—Research support from the National Institutes of Health, European Union, and Health Resources Service Administration; consultant for Amgen, Bayer, BG Medicine, Cardiocell, Celladon, Gambro, GE Healthcare, Medtronic, Novartis, Ono Pharma, Takeda, Trevena, and Zensun.

JAE—disclosures available online at www.vigour.ualberta.ca.

GMF—Consultant for Novartis, Amgen, Trevena, Roche Diagnostics, Singulex, Sorbent Therapeutics, and BMS; research funding from NIH, Novartis, Amgen, and Roche Diagnostics.

GJF—Research support from Novartis, Cardiorentis, Trevena, Portola, Radiometer, Medtronic, Siemens, Insys, The Mayday Foundation, and Pfizer; advisory board for Intersection Medical, Janssen, Insys, and The Medicines Company.

GCF—Consultant for Medtronic, Novartis, and Johnson and Johnson.

MMG—Scientific advisory board for Merck, Janssen, and Cardioxyl; grant support from NHLBI.

BH—Consulting relationship with Motive Medical Intelligence, Insight PD, and Intersection Medical Inc.; advisory board for Janssen Pharmaceuticals; research funding from The Medicines Company, Sanofi Aventis, Dyax, Radiometer, Cardiorentis, and Novartis.

JG—Consultant for Novartis.

DL—Consultant for Bayer, Otsuka, Covis, Biocontrol, and Janssen.

PDL—Consultant for Novartis Pharmaceuticals, Trevena Inc., Intersection Medical, The Medicines Company, Ostuka, Janssen, Astellas, AstraZeneca, Beckman Coulter; research grant/support from Novartis Pharmaceuticals, Cardiorentis Inc., Trevena Inc., Intersection Medical, Mespere, and BG Medicine; support from NIH/NIMHD 5 R01 MD005849-04.

PSP—Consultant for Janssen, Medtronic, Novartis, Trevena, SpringLeafTx, BG Medicine, and Cornerstone Therapeutics; research support from Abbott, Alere, and NIH.

WFP—Research from Abbott, Alere, Banyan, Cardiorentis, Portola, Roche, and The Medicines Company; consultant for BG Medicine, Beckman, Boehringer-Ingelheim, Instrument Labs, The Medicine's Company; consultant for Alere, Cardiorentis, and Janssen; ownership interests in Comprehensive Research Associates LLC and Emergencies in Medicine LLC.

DBS—Grant support and consultant for Acorda Therapeutics Inc.

JT—Consulting fees/research grants from Amgen, Cardio3 Bioscience, Cytokinetics, Novartis, Sorbent Therapeutics, St. Jude, and Trevena.

DJL—none.

(GJF), Cincinnati, OH; the Department of Emergency Medicine, Harvard Medical School (MMG), Boston, MA; the Department of Emergency Medicine, Wake Forest University (BH), Winston-Salem, NC; the Department of Emergency Medicine, Thomas Jefferson University (JEH), Philadelphia, PA; the Department of Emergency Medicine, Northwestern University (PSP), Chicago, IL; the Department of Emergency Medicine, Baylor University (WFP), Houston, TX; the Division of Cardiology, Cleveland Clinic (NA), Cleveland, OH; the Division of Cardiology, Emory University (JB), Atlanta, GA; the Division of Cardiology, University of Alberta (JAE), Edmonton, Alberta, Canada; the Division of Cardiology, Duke University (GMF), Durham, NC; the Division of Cardiology, Ronald Reagan-UCLA Medical Center, (GCF) Los Angeles, CA; the Division of Cardiology, Wayne State University (DEL), Detroit, MI; the Division of Cardiology, San Francisco Veterans Affairs Medical Center, University of California at San Francisco (JRT), San Francisco, CA; and the Division of Cardiology, Vanderbilt University, Nashville Veterans Affairs Medical Center (DJL), Nashville, TN

Abstract

Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1 million emergency department (ED) visits and over 1 million annual hospital discharges. The majority of inpatient admissions originate in the ED; thus, it is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. This article discusses contemporary ED management as well as the necessary next steps for ED-based acute HF research.

Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1 million emergency department (ED) visits and over 1 million annual hospital discharges.^{1,2} An aging population and improved survival from cardiovascular diseases is expected to further increase HF prevalence.³ By 2030 an estimated 25% increase in HF prevalence will result in an additional 3 million affected individuals.^{1,4} Of the \$39.2 billion spent on HF care in the US in 2010, inpatient admissions accounted for the single largest proportion. By 2030, the amount spent on hospital care for HF will be even greater as annual total costs are expected to be close to \$70 billion.

Emergency providers play a significant role in the management of patients with acute heart failure (AHF). Therapeutic and disposition decisions made by emergency providers have direct impact on morbidity, mortality, and hospital length of stay, all of which affect health care costs.⁵⁻⁹ Over 80% of ED patients with AHF are admitted to the hospital, a proportion that has remained largely unchanged over the past 5 years.² It is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. Equally important are partnerships between emergency providers and HF specialists along with the entire interdisciplinary team caring for HF patients to streamline care from the ED to the inpatient and outpatient settings.

CURRENT APPROACHES TO DIAGNOSIS

Although there is no universally accepted terminology to describe “acute” HF, for the purpose of clarity we have chosen to use AHF, defined as chronic or de novo HF with new or worsening symptoms requiring acute therapy. Patients present to the ED with signs and symptoms, not diagnoses. While dyspnea is the most common symptom in AHF, it has a large differential diagnosis. Efficient diagnosis is critical as delays in the delivery of care for AHF are associated with increases in mortality, hospital length of stay, and treatment costs.^{10–14} Thus, an understanding of the strengths and limitations of the history, physical examination, and laboratory and radiographic tests used to assist in the diagnosis of AHF is essential.

History and Physical Examination

Multiple studies suggest that there is no historical or physical examination finding that achieves a sensitivity and specificity of >70% for the diagnosis of AHF. Further, only one clinical finding, the S3 gallop, achieves a positive likelihood ratio (LR+) greater than 10 and none carries a negative likelihood ratio (LR–) less than 0.1.¹⁴ In a meta-analysis of 18 studies,¹³ prior HF was the most useful historical parameter, with a LR+ of 5.8 and LR– of 0.45, respectively. Dyspnea on exertion is the symptom with the lowest LR– at 0.48, but has a LR+ of only 1.3^{13,14} while paroxysmal nocturnal dyspnea, orthopnea, and peripheral edema have the best LR+ (2/1–2.6%), but a notably poor LR– (0.64–0.70).^{13,14} Notably, emergency physician clinical judgment is only modestly useful with a LR+ of 4.4 and LR– of 0.45.¹³ Although the S3 has the highest LR+ (11), it has far less utility as a negative predictor (LR–, 0.88)¹³ and suffers from poor inter-rater reliability.^{15–18} Hepatojugular reflux (LR+, 6.4) and jugular venous distension (LR+, 5.1) are the only other examination findings with a LR+ above 5.

Chest Radiography

Chest radiographs demonstrating pulmonary venous congestion, cardiomegaly, and interstitial edema are the most specific test findings for AHF (Table 1).^{12,13} However, their absence cannot rule out AHF, as up to 20% of patients with AHF will have no congestion on their ED chest radiograph.¹⁹ Particularly in late-stage HF, patients may have few radiographic signs, despite AHF symptoms and elevated pulmonary capillary wedge pressure (PCWP).^{12,20,21}

Electrocardiogram

The electrocardiogram is not useful for diagnosis, but may suggest a specific cause or precipitant of AHF such as myocardial ischemia, acute myocardial infarction, or arrhythmia. The presence of atrial fibrillation has a high LR+ for AHF; however, new t-wave changes are also associated with AHF (Table 1).¹³ The electrocardiogram may also offer clues as to the underlying cause of chronic HF (e.g., Q waves in ischemic cardiomyopathy, low voltage in cardiac amyloid).

Biomarkers

The natriuretic peptides (NP) B-type NP (BNP) and its precursor N-terminal Pro-BNP are the most established AHF diagnostic biomarkers. They add value in the setting of undifferentiated dyspnea by improving diagnostic discrimination^{22,23} and correlate with cardiac filling pressures and ventricular stretch.²⁴ NP testing is a Class 1 (best evidence) guideline recommendation by both Heart Failure Society of America (HFSA) and American College of Cardiology Foundation/American Heart Association (ACCF/AHA)^{25,26} and may be particularly useful when the etiology of dyspnea is unclear and have been shown to have greater utility than chest x-ray for diagnosing AHF.^{13,22} Newer markers, such as ST2 and galectin 3, have been explored for prognostic assessment and diagnosis of preclinical HF,^{27,28} but their role in the ED is less clear.

NP levels can be affected by age, gender, weight, and renal function (Table 2).²⁹ Dyspnea not due to AHF can still be associated with NP elevation in a variety of conditions associated with myocardial stretch (e.g., right ventricular stretch from pulmonary hypertension or pulmonary embolism, acute coronary syndromes) or decreased renal clearance.^{30–32} Patients with HF with preserved left ventricular ejection fraction have a smaller left ventricular radius and thicker walls compared to patients with reduced left ventricular ejection fraction (LVEF; HFrEF) resulting in proportionally lower NP levels for similar degrees of AHF, suggesting that different diagnostic thresholds are needed depending on whether LVEF is preserved or reduced.³³ Beyond clinical factors, additional variation in NP levels can arise from heritable³⁴ and specific genetic variants that have been shown to alter assay performance.³⁵ In general, changes over 50% from baseline represent worsening HF; however, significant variation in NP levels can occur within the same patient and intraindividual differences between measurements do not necessarily represent an acute clinical event.³⁶ Despite these limitations and a substantial “gray zone” when interpreting results, NP testing remains useful and is additive to physician assessment.³⁷

Point-of-care Ultrasonography

While not a substitute for comprehensive echocardiography, point-of-care cardiac ultrasonography can be valuable in determining the etiology of dyspnea, providing an assessment of left ventricular function and volume status and looking for signs of pericardial effusion. Point-of-care ultrasonography can accurately estimate LVEF, has good inter-rater reliability, and is most likely to be of use immediately or shortly after ED arrival in those patients without a prior HF diagnosis.²⁰ Volume status may be assessed by inferior vena cava (IVC) diameter and its degree of change with respiratory variation. Inspiration causes the IVC to decrease in size as more blood leaves the IVC than collecting within it.^{38,39} The IVC collapse index, defined as IVC diameter during expiration minus the IVC diameter during inspiration divided by IVC diameter during expiration, can help determine volume status in the setting of AHF. In AHF patients with volume overload the IVC is dilated without the normal amount of change in IVC diameter during the respiratory cycle. Thus the IVC collapse index is closer to 1, compared to patients without HF where it is typically between 0.25 and 0.75.⁴⁰

Lung water can also be assessed with ultrasound by looking for sonographic B-lines (also called lung comets or comet tail artifacts) each of which implies thickened interstitial or fluid-filled alveoli. B-lines occur most commonly in patients with AHF and correlate with elevated PCWP and extravascular pulmonary water.⁴¹ In the ED setting, the presence of B lines on pleural ultrasonography is associated with fluid overload, enhancing diagnostic accuracy when coupled with examination and NP measurement.⁴² *Several authors have shown that bedside pulmonary ultrasound is accurate in detecting AHF with reported sensitivities of 86%–100% and specificities of 95%–98% (LR– of 0.01–0.14 and LR+ of 17.2–49.5).*^{43,44} Ultrasonography has been shown to be more accurate than auscultation or chest radiography for the detection of pleural effusion, consolidation, and alveolar interstitial syndrome in the critical care setting.⁴⁵

Other Diagnostic Technologies

Obtained using stand-alone machines or from an implanted cardiac device, impedance cardiography (ICG) may provide an additional hemodynamic measure.^{46–48} However, studies evaluating the utility of externally applied ICG devices to guide acute therapy have had mixed results^{49,50} and their role in the ED remains unclear. Further, while implanted devices offer extensive monitoring capabilities (heart rate, heart rate variability, activity level, thoracic impedance) for chronic HF disease management,⁵¹ their utility in the ED is not established. Because data from indwelling devices provide important diagnostic information, they may ultimately prove useful, particularly for subtyping HF based on hemodynamics, developing tailored treatment strategies, and quantifying fluid status to aid in transition care decisions. Routine interrogation of implantable pacemakers or cardioverter-defibrillators, which provide ongoing rhythm recordings, can be used to assess for atrial and/or ventricular arrhythmias as precipitants to AHF.⁵² Additional technologies to assist with noninvasive hemodynamic assessment such as finger cuff pulse-wave analysis may also be of value but their utility in the ED has yet to be determined.⁵³

CURRENT GUIDELINE RECOMMENDATIONS FOR AHF THERAPY

The ACCF/AHA Guidelines for the Management of HF is a comprehensive document using standardized methodology to evaluate the available evidence for HF management,²⁶ with one section providing guidance on the hospitalized patient. While the guidelines do not provide specific recommendations on the early evaluation and management of AHF, they do suggest continuation and initiation of guideline-directed medical therapy (GDMT) for the hospitalized patient, which can be somewhat extrapolated to the ED phase of care. GDMT may include angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta blockers, mineralocorticoid antagonists depending on variables such as race, LVEF, and contraindications. For instance, in patients with HFrEF, it is recommended (Class I, LOE B) that, in the absence of hemodynamic instability or contraindications, GDMT be maintained and furthermore it is reasonable to consider early administration of such oral therapy in the ED. Other recommendations relevant to early care (Table 3) include initiation of intravenous (IV) loop diuretics at a dose greater than or equal to their chronic oral daily dose (Class I, LOE B), consideration of parenteral nitrates (nitroglycerin, nitroprusside) or nesiritide as

adjuvant therapy for nonhypotensive patients with continued symptoms (Class IIb, LOE A) and broad use of thromboembolism prophylaxis (Class I, LOE B).

Using methodology similar to ACCF/AHA, the HFSA published Comprehensive Practice Guidelines in 2010.²⁵ Section 12 of this guideline focuses on AHF and suggests that treatment start with clinical classification based on history, examination, and secondary risk stratification using diagnostic adjuncts. In general, the recommendations are consistent with the ACCF/AHA (Table 3) but the HFSA guidelines specifically mention noninvasive ventilation in patients with severe pulmonary congestion (strength of evidence [SOE] A) and suggest that inotropic therapy (milrinone, dobutamine) be considered in patients with signs of diminished end-organ perfusion, LV dilatation, reduced EF, and marginal systolic blood pressure (<90 mm Hg) or in those who are poorly responsive to diuretics or are intolerant to vasodilators (SOE C). An update to the HFSA guideline on AHF was published in 2013⁵⁴ and provides information on recently published trials^{55–57} that have yielded important data to inform both current clinical practice and future research directions.

The European Society of Cardiology (ESC) guidelines section 12 specifically addresses the treatment of AHF.⁵⁸ Overall, the ESC Guidelines represent an approachable, clinically relevant synopsis of the available evidence in the treatment of patients with AHF (Table 3). Formatted to address clinical scenarios these guidelines provide treatment recommendations for AHF patients with pulmonary congestion, hypotension, acute coronary syndrome, atrial fibrillation with rapid ventricular response, heart block, isolated right ventricular failure, cardiorenal syndrome, and adult congenital heart disease. While the recommendations are generally consistent with the ACCF/AHA and HFSA, the ESC makes a few additional pertinent recommendations. The use of IV opiates with antiemetics was given IIa (LOE C) recommendation for patients who are anxious, restless, or distressed. When using opiates, the authors suggest close monitoring and caution regarding respiratory depression, which may be important to prevent adverse events, as suggested in a recent analysis.⁵⁸ With respect to invasive monitoring, an arterial line or a pulmonary artery catheter is recommended only in patients with refractory hypotension, in whom LV filling pressures are uncertain or who are surgical candidates.

The American College of Emergency Physicians (ACEP) does not publish comprehensive guidelines, focusing instead on clinical policy statements targeted at critical aspects of ED care for common conditions. In 2007, ACEP produced their only clinical policy dedicated to AHF. In it, some of the more controversial and important issues confronting ED management of AHF were addressed; however, significantly more data have become available since its publication.^{55,59,60}

CURRENT ED THERAPY: APPLICABILITY OF RECENT EVIDENCE AND ONGOING TRIALS

Current Approach to ED Treatment of AHF

It is noteworthy that neither the ACCF/AHA nor the HFSA guidelines include any Class I, Level A recommendations for the pharmacologic treatment of AHF.^{25,26,58} ED treatment is not emphasized in the expert recommendations from the ACCF/AHA, and little has changed

regarding AHF treatment in the ED since the 1970s.^{26,61} This is not a reflection upon guidelines; rather, it highlights the absence of robust ED clinical trial data and an ill-defined standard practice (Table 4).

AHF Treatment: Consideration of Presenting Blood Pressure

Expert opinion, supported by smaller cohort and randomized studies, suggests that our current approach should reconsider the “diuretics-only” treatment paradigm and incorporate other clinical parameters into the initial management of AHF.^{12,62} While several classification schemes are proposed; none have been prospectively validated. *There have been no randomized trials evaluating ED treatment strategies based on initial blood pressure.* Based on prior and recent evidence we suggest an initial treatment approach based on presenting systolic blood pressure (SBP),^{63–67} dividing patients into three groups (Table 5): 1) hypertensive (SBP > 140 mm Hg), 2) normotensive (SBP 100–140 mm Hg), and 3) hypotensive (SBP < 100 mm Hg).¹² This approach is based on the initial BP (ambulance or ED) and not BP measurements taken several hours later, after initial ED management.

Elevated SBP may be an especially important target, as a sizable proportion of patients with hypertensive AHF present with volume redistribution rather than volume overload as their predominant phenotype. In such patients, congestion is due to increased afterload with rapid onset of dyspnea and flash pulmonary edema representing a classic presentation.⁶⁴ Rarely do these patients complain of symptoms days to weeks prior to presentation; rather, symptoms are abrupt and with less evidence of peripheral edema or weight gain.^{68,69} While elevated systemic vascular resistance is thought to be the primary mechanism, volume mobilization from the large venous reservoir contained within the splanchnic circulation has also been proposed as a contributory mechanism.⁷⁰ For volume overload patients, IV loop diuretics remain the primary ED pharmacologic therapy, but for those with volume redistribution vasodilation may be the preferred approach to treatment. Small studies suggest safety and significant clinical benefit with nitrates or calcium channel blockers in the hypertensive AHF phenotype^{63,66,67} and results from several ongoing, large trials of targeted vasodilator therapy are eagerly anticipated.

This simple approach prompts greater usage of vasodilators, as approximately 50% of patients have a SBP > 140 mm Hg.⁶⁸ However, independent of BP, an assessment of volume status is critical as patients in any group may still require diuresis. This is particularly true for hypotensive patients as many will have a low SBP at baseline and fluid overload may still be present. Importantly, for such patients inotropes should only be used when other treatments have failed or there is clear evidence of shock or organ hypoperfusion.²⁵

Clinical Trials Evidence in AHF: Past and Current

Hospitalizations, once viewed as episodes of fluid overload requiring IV diuretics in an otherwise stable chronic HF course, are now recognized as a fundamental change in the clinical trajectory of patients with HF. Whether AHF simply heralds a sicker chronic HF cohort or reflects a distinct pathophysiologic entity is unclear. Compared to outpatients with a comparable degree of cardiac dysfunction, hospitalized patients have significantly worse outcomes.^{71,72} Despite an improved understanding of the pathophysiology and prognosis of

patients with AHF, treatment remains primarily targeted at short-term decongestion using diuretics and, to a much lesser degree, vasodilators. Multiple Phase III clinical trials failed to show clear improvement in symptoms, survival, or rehospitalization rates.^{60,73–79}

Although IV nitroglycerin is commonly used in AHF, there are no large randomized trials evaluating its impact on long-term outcomes.⁸⁰ A recent study of low-dose dopamine and low-dose nesiritide in patients with AHF and renal dysfunction showed no impact on renal function or clinical outcomes for either agent compared to placebo.⁸¹ In the DOSE trial, there were no significant differences in dyspnea improvement or worsening renal function between intermittent bolus or infusion of furosemide. Higher-dose diuretic regimens demonstrated a nonsignificant improvement in dyspnea and slightly higher risk of worsening renal function, when compared to the low-dose strategy.⁸¹ None of these studies assessed the cost-effectiveness of care and very few enrolled AHF patients in the ED.

DISPOSITION DECISION MAKING: CAN A SUBSET OF ED PATIENTS BE SENT HOME?

The ED is increasingly being relied on to evaluate more complex patients, some of whom previously were directly admitted from an outpatient setting.⁸² As a result, emergency physicians serve as major decision-makers for approximately half of all U.S. inpatient admissions for AHF.⁸³ However, this may present challenges as emergency physicians have a low tolerance of “risk” in relation to ED discharge decisions. For AHF, a less than 0.5% risk of 30-day death or serious nonfatal complication (*acute myocardial infarction, reperfusion therapy, respiratory failure, or cardiopulmonary resuscitation*) has been suggested as an emergency physician’s typical threshold for ED discharge, a proportion most likely lower than for cardiologists or primary care providers.⁸⁴ Collaborative decision-making coupled with capacity for close follow-up may safely change the dominant flow of patients from the ED to the inpatient setting.

Compounded by a lack of disposition recommendations from national guidelines, the absence of validated decision tools identifying patients with limited susceptibility to postdischarge events,^{12,85} and high rates of relapse and mortality after an ED discharge,^{86,87} such risk intolerance leads to admission for more than 80% of patients treated in the ED for AHF. Consensus guidelines have addressed AHF risk stratification, but provide little objective instruction for ED disposition decision-making²⁶ or base recommendations on disparate studies of isolated predictors.^{25,88}

Prediction of Low Risk

There have been many investigations of high-risk physiologic markers in ED patients with AHF (Table 6), but most were retrospective, involved hospitalized patients, lacked a measurement of additive value to clinical assessment, and did not use a rigorous AHF diagnostic standard.^{89,90} These limitations notwithstanding, renal dysfunction, low blood pressure, low serum sodium, and elevated cardiac biomarkers (troponin or NP) have been consistently associated with an increased risk of morbidity and mortality.⁹¹ As the majority of patients are already admitted to the hospital, characterizing AHF clinical profiles safe for

either ED discharge, or discharge after a brief period of treatment and observation, would be of even greater utility. Unfortunately, risk prediction instruments in AHF have been largely unsuccessful when attempting to define a cohort of patients safe for early discharge and at low-risk of 30-day mortality and readmission.^{92,93} More importantly, risk tools have not been implemented in the ED to determine how they augment, or detract from, clinician judgment. As a result, published tools have had little impact on ED disposition decision-making. Those patients with high-risk features or significant comorbidities need, and often benefit from, inpatient admission. However, up to 50% of hospital admissions may not be necessary and should be the focus of future research.^{94,95}

Previous studies have defined 30-day AHF readmission rates of 15%–20% and mortality rates of less than 1% as “low-risk” characteristics in ED patients.^{84,95–98} A rule derived and validated in two separate AHF data sets identified a subset of 19.2% of patients who would be considered low risk for 30-day morbidity and mortality.^{10,99} However, its additive value on top of clinical judgment has yet to be prospectively tested. An evaluation of four AHF prediction rules suggests that they would have limited utility to help emergency providers identify patients safe for discharge.¹⁰⁰

In a Canadian study of over 12,000 patients, a prediction rule for 7-day mortality was derived and validated. Their model (Table 7) suggests several ED variables can be used to categorize patients at low-risk of 7-day mortality. However, this study had several limitations including retrospective patient identification, excluding early readmission for AHF as an outcome in the model, a lack of prospective testing compared to clinician judgment, and a practice environment not reflective of the United States.⁸⁸

Current Challenges in ED Disposition Decisions

What remains elusive from the ED standpoint is defining who, despite a reassuring clinical profile, is at risk for early readmission, cardiovascular events, or death after discharge home. Compared to a group with worsening renal and cardiac biomarker profiles, as well as an increased risk of 180-day mortality, those with more reassuring biomarker profiles and a decreased risk of mortality unfortunately have a similar risk for readmission.^{56,101}

Multidimensional criteria, such as McKesson Interqual¹⁰² or Milliman Care Guidelines,¹⁰³ are widely used by hospital utilization management to guide and justify level of care (e.g., discharge, observation, inpatient floor, or intensive care unit [ICU]). Their purpose is to help health care organizations assess the clinical appropriateness and safety of patient services across the continuum of care, whether prospectively, concurrently, or retrospectively. While they may serve as a useful tool for real-time risk stratification of AHF patients, the small amount of evidence evaluating the accuracy of such criteria in determining appropriate ED disposition for AHF suggests they are limited.¹⁰⁴

Among patients stable for discharge, early follow-up is critical and has been associated¹⁰⁵ with a decreased risk of readmission. Collaborative postdischarge follow-up involving cardiology and primary care has also been associated with better guideline adherence and lower mortality.¹⁰⁶ Further, disease management programs providing close monitoring and follow-up have lowered readmission rates.¹⁰⁷ Connecting low-risk patients to these

programs represents an opportunity that should be systematically evaluated. Unfortunately, assurance of follow-up postED care is challenging and even the best risk prediction tool may not be able to influence physician or patient behavior and facilitate discharge after initial management in the ED.^{8,84}

Beyond Physiologic Risk Predictors

Social, behavioral, and environmental factors strongly influence one's ability to implement the lifestyle changes required to optimally manage a chronic illness.^{108,109} Furthermore, patient self-care, and implementing strategies to overcome barriers to successful self-care, are associated with optimal outpatient management and reduced readmissions.^{110–114} Unfortunately, emergency physicians have largely avoided the complex social, environmental, and behavioral aspects of chronic HF care. Attempts to address these issues in the ED are often thwarted by the lack of the necessary resources or time. Factors unrelated to acute treatment (e.g., health literacy and numeracy, disease knowledge, symptom monitoring, transportation) result in patients being admitted for further management of AHF, despite objective evidence of stability. Combining future risk prediction instruments with clinicians' judgment as well as obtaining and addressing patients' self-care barriers may provide the tools necessary to change physicians' practice patterns.⁸⁵

Recommendations

To augment clinical judgment when making disposition decisions, we suggest that ED patients with AHF be divided into three broad categories (Figure 1). Those at high risk for mortality or serious adverse events should be admitted to the hospital, with an ICU admission needed in those who require invasive monitoring, ventilator support, or other ICU-level treatment. Those without high-risk features should be further risk stratified based on active comorbidities, response to initial therapy, and their ability to manage their illness as an outpatient. Those with active comorbidities or significant self-care barriers may be better suited for inpatient management. Those without active comorbidities who have an incomplete response to initial therapy may be ideal candidates for an observation unit (OU). Candidates for ED discharge are those with adequate response to ED therapy and no high-risk markers, significant comorbidities, or self-care barriers.

OBSERVATION UNITS AND OBSERVATION SERVICES: THEIR ROLE IN ED PATIENTS WITH AHF

The pathway from ED to inpatient for AHF patients may not be the best use of resources, as relatively few require intensive acute care, mechanical ventilation, mechanical or pharmacologic circulatory support, or undergo invasive diagnostic or therapeutic interventions.^{115,116} The majority of AHF patients require IV diuresis in a monitored setting until symptoms subjectively improve. These patients, especially if they do not require a prolonged hospital stay, may best be ideal candidates for observation services.

Observation Services

Observation is a billing status indicating a patient is still an outpatient, although they may be receiving care in a hospital or ED-based setting. The rules governing observation status, as generated by the Center for Medicare and Medicaid Services (CMS) and generally followed by private payers, have undergone many changes since their inception in the 1990s. However, CMS has been consistent in that observation services should not span more than 48 hours and generally should necessitate 24 hours or less. Despite this, the mean length of stay for adult general medical patients in observation status is 41.1 hours, with 26% of stays lasting greater than 48 hours.¹¹⁷

Observation status is independent of the actual location of care delivery. The most common, and likely least efficient, approach involves intermixing observation patients among the general medical population.¹¹⁸ While this approach requires the least in terms of infrastructure and resources, it frequently results in lengths of stay beyond the typical 24 to 48 hours. Generally, patients appropriate for observation care will be less ill; they will require less intensive monitoring than higher acuity inpatients on the same service or hospital unit. A more efficient model is to geographically cluster observation patients in a unit that is designed explicitly to deliver care to the short-stay population by inpatient specialists,¹¹⁹ hospitalists,^{120,121} or emergency providers (representing 56% of all dedicated OUs).¹¹⁸ This placement may facilitate the goals of providing frequent reassessment, adjustment of treatment needs based on response to therapy, and ready access to adjunctive diagnostic studies so the decision to discharge or admit the patient can be made within 24 hours of presentation.

AHF and Observation Care

Many patients with AHF may be ideal for management in an observation setting. Frequent reassessment, diuresis, afterload reduction, and targeted patient education can be accomplished in a relatively short time. In consultation with cardiology or primary care providers, outpatient medication regimens can be adjusted, and where available, patients can be linked with specialty HF programs upon discharge. While prospective, randomized, controlled trials evaluating this strategy are lacking, preliminary evidence suggests AHF patients managed in an OU setting have similar outcomes and improved resource utilization compared to a risk-matched group of admitted patients.^{122,123}

The Society for Cardiovascular Patient Care (formerly the Society of Chest Pain Centers) published evidence- and consensus-based guidelines for patient selection and management in the observation setting,¹²⁴ which were later externally validated in an independent data set (Table 8).⁹⁵ However, the evidence base behind such recommendations is still not robust. As suggested previously, the absence of high risk does not equate to being low risk. Therefore, it may be easier to define who is *not* appropriate for short stay/OU care. In addition to those measures in Table 7, patients requiring acute critical care measures such as aggressive titration of parenteral vasoactive medications or ongoing noninvasive positive pressure ventilation after initial stabilization are candidates for a critical care unit, not an OU. Patients with minimally elevated troponin levels may still be candidates for observation management, especially if serial troponin measurements are followed to exclude ACS.

However, patients with a mildly elevated troponin are at increased risk for “failing” observation care and requiring inpatient management.⁹⁷ Likewise, patients with complex psychosocial needs, such as end-stage HF or lack of social support necessitating consideration of skilled nursing facility placement, frequently need inpatient resources. Conversely, simpler social barriers, such as medication availability, lack of follow-up care, or patient education may be addressed in an observation setting.

UNANSWERED QUESTIONS AND FUTURE RESEARCH AGENDA

While the need to alter the current course of research related to AHF is widely recognized, there is a lack of clarity on the specifics of a new agenda.⁵⁴ For new therapies, does lack of clinical trial success reflect an absence of drug efficacy, suboptimal study design, or both? Indeed many trials may appear unsuccessful due to the heterogeneous nature of the AHF population. Targeting therapy to more specific patient characteristics and avoidance of a one-size-fits-all approach is an important alternative to explore. However, it is unclear what agents are best for a given phenotypic variant and precisely when they should be administered during the course of treatment. Evolving data suggest that early interruption of acute pathophysiology may be a critical consideration, but it can take time for certain perturbations to manifest, and intervention before adequate information has been obtained may increase the potential for therapeutic misalignment. The hypothesis that early treatment with effective novel agents may limit organ damage and improve outcomes has gained momentum in recent years but study of this concept is just beginning.^{56,63,101,125}

In addition to therapeutic considerations, there is a need to better define clinically meaningful endpoints of acute intervention. Dyspnea resolution remains the most common goal of treatment and is undoubtedly an important patient-centric outcome, but its subjective nature has made standardization challenging. Moreover, dyspnea correlates poorly with in-hospital worsening HF and postdischarge events (e.g., readmission and mortality) making it difficult to rely on as the sole measure of improvement.^{126–129} Maneuvers that illicit cardiac stress through provocation with position change (i.e., seated to supine) or physical exertion (i.e., walk tests) may help delineate more subtle effects of AHF on dyspnea and thus serve as more definitive measures of clinical improvement, but have yet to be tested in prospective trials.¹³⁰ Further, other HF symptoms, such as fatigue and body swelling, may be as meaningful as dyspnea to patients and important patient-centered endpoints to explore.¹³¹ The assessment of frailty, especially in older patients, has also recently evolved as an important marker of risk and prognosis and may become a routine part of the predischarge “bundle.”¹³²

Testing Novel Approaches to Therapeutic Decision-making

To address such unanswered questions and help shape the future research agenda for AHF, new approaches to therapeutic decision-making must be developed. To better understand potential confounders and identify the ideal target population, therapeutic trials are increasingly looking toward timing of intervention and targeted phenotypic groups. Understanding the ED has an active role in the initial management and disposition of AHF patients, many of these trials have focused on inclusion of emergency physicians, both as part of trial design and as principal investigators. Highly successful for acute myocardial

infarction trials, such a collaborative approach offers promise for early patient identification and more comprehensive recruitment.

While commonly available parameters such as blood pressure and measures of renal function and myocardial injury are currently used to define patient subgroups, there is growing interest in the utility of biomarkers to enhance phenotypic granularity. Although inclusion and exclusion criteria often consider biomarker profiles, targeting a specific therapy to one biomarker has yet to be implemented in a large-scale study. Trials aimed at administration of a specific drug to a biomarker which identifies patients most likely to benefit are under consideration. Quite unique, this approach would represent a further departure from the one-size-fits-all methodology and facilitate truly tailored therapy. Finally, the use of implantable hemodynamic monitors to assess intracardiac filling pressures and guide outpatient therapy may reduce the burden of AHF on the department, but require more study.¹³³

Testing Novel Approaches to Disposition Decision-making

With increasing pressure to avoid unnecessary hospitalizations, there is tremendous interest in improving on the process of patient disposition. While much research has focused on risk stratification for AHF patients with development of pathways for disposition based on presence or absence of clearly defined variables, little attention has been directed toward the determination of when sufficient cardiac unloading has occurred. Improvement in dyspnea is typically used to demonstrate treatment effectiveness, but there is often no uniform means to determine this beyond patient self-report, making it difficult to quantify differences from one patient to another. As noted, novel implantable hemodynamic monitors or noninvasive hemodynamic tools may allow clinicians to assess change in filling pressures and optimize timing of discharge and early follow-up.¹³⁴

Basing disposition on the absence of dyspnea after provocation would be a novel approach to help ensure that symptoms have fully resolved. Studies to test this endpoint are clearly needed. However, even after several days of in-hospital treatment, residual dyspnea is common¹²⁹ and additional measures to evaluate the effect of treatment on myocardial stress would be beneficial. Although NP levels are strongly associated with cardiac dysfunction, studies of NP guided management have yielded mixed results.^{9,135} Other biomarkers may be useful for this purpose but to date, none have been clearly identified. Finally, alternative endpoints should be explored. Total days alive out of the hospital, or total hospital days, over a 30-day period, may be more useful than 30-day readmission rates when evaluating the impact of a novel diagnostic or therapeutic investigation on AHF care.

CONCLUSIONS

With the rising prevalence of heart failure and the ED serving as the primary entry point for the majority of acute heart failure admissions, emergency providers will continue to play a critical role in acute heart failure management. Early acute heart failure treatment has begun to evolve from largely a diuretic-only strategy to one that also considers blood pressure management as part of the initial approach. Clinical trials must be conducted in the ED to improve the evidence base and drive optimal initial therapy for acute heart failure. Should

ongoing and future studies suggest early phenotype-driven therapy improves in-hospital and postdischarge outcomes, ED treatment decisions will need to evolve accordingly. The potential impact of future studies that incorporate risk stratification into ED disposition decisions cannot be underestimated. Predictive instruments that identify a cohort of patients safe for ED discharge, while simultaneously addressing barriers to successful outpatient management, has the potential to significantly impact quality of life and resource expenditures.

References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. *Circulation*. 2011; 123:e18–e209. [PubMed: 21160056]
2. Storrow AB, Jenkins CA, Self WH, et al. The burden of acute heart failure on U.S. emergency departments. *JACC Heart Fail*. 2014; 2:269–77. [PubMed: 24952694]
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. *Circulation*. 2014; 129:e28–e292. [PubMed: 24352519]
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation*. 2011; 123:933–44. [PubMed: 21262990]
5. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. *Congest Heart Fail*. 2009; 15:256–64. [PubMed: 19925503]
6. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. *J Am Coll Cardiol*. 2008; 52:534–40. [PubMed: 18687247]
7. Brar S, McAlister FA, Youngson E, Rowe BH. Do outcomes for patients with heart failure vary by emergency department volume? *Circ Heart Fail*. 2013; 6:1147–54. [PubMed: 24014827]
8. Rame JE, Sheffield MA, Dries DL, et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. *Am Heart J*. 2001; 142:714–9. [PubMed: 11579364]
9. Singer AJ, Birkhahn RH, Guss D, et al. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. *Circ Heart Fail*. 2009; 2:287–93. [PubMed: 19808351]
10. Hsieh M, Auble TE, Yealy DM. Validation of the Acute Heart Failure Index. *Ann Emerg Med*. 2008; 51:37–44. [PubMed: 18045736]
11. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. *Arch Intern Med*. 2006; 166:1081–7. [PubMed: 16717170]
12. Collins S, Storrow AB, Kirk JD, Pang PS, Diercks DB, Gheorghiu M. Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. *Ann Emerg Med*. 2008; 51:45–57. [PubMed: 17868954]
13. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? *JAMA*. 2005; 294:1944–56. [PubMed: 16234501]
14. Wong GC, Ayas NT. Clinical approaches to the diagnosis of acute heart failure. *Curr Opin Cardiol*. 2007; 22:207–13. [PubMed: 17413277]
15. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. *N Engl J Med*. 2001; 345:574–81. [PubMed: 11529211]
16. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. *J Heart Lung Transplant*. 1999; 18:1126–32. [PubMed: 10598737]

17. Collins SP, Lindsell CJ, Peacock WF, et al. The combined utility of an S3 heart sound and B-type natriuretic peptide levels in emergency department patients with dyspnea. *J Card Fail.* 2006; 12:286–92. [PubMed: 16679262]
18. Collins SP, Lindsell CJ, Peacock WF, Hedger VD, Storrow AB. The effect of treatment on the presence of abnormal heart sounds in emergency department patients with heart failure. *Am J Emerg Med.* 2005; 24:25–32. [PubMed: 16338505]
19. Collins SP, Lindsell CJ, Storrow AB, Abraham WT. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. *Ann Emerg Med.* 2006; 47:13–8. [PubMed: 16387212]
20. Volpicelli G, Caramello V, Cardinale L, Mussa A, Bar F, Frascisco MF. Bedside ultrasound of the lung for the monitoring of acute decompensated heart failure. *Am J Emerg Med.* 2008; 26:585–91. [PubMed: 18534289]
21. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. *Am J Med.* 1991; 90:353–9. [PubMed: 1825901]
22. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med.* 2002; 347:161–7. [PubMed: 12124404]
23. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. *Acad Emerg Med.* 2003; 10:198–204. [PubMed: 12615582]
24. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. *Am Heart J.* 1998; 135:825–32. [PubMed: 9588412]
25. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail.* 2010; 16:e1–194. [PubMed: 20610207]
26. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013; 62:e147–239. [PubMed: 23747642]
27. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulis P, Butler J, Giamouzis G. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. *Curr Heart Fail Rep.* 2013; 10:441–9. [PubMed: 24142671]
28. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. *Eur J Heart Fail.* 2010; 12:826–32. [PubMed: 20525986]
29. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. *Am Heart J.* 2004; 147:1078–84. [PubMed: 15199359]
30. Pasha SM, Klok FA, van der Bijl N, de Roos A, Kroft LJ, Huisman MV. NT-pro-BNP levels in patients with acute pulmonary embolism are correlated to right but not left ventricular volume and function. *Thromb Haemost.* 2012; 108:367–72. [PubMed: 22740123]
31. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. *Hypertension.* 2005; 46:118–23. [PubMed: 15939804]
32. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. *J Rheumatol.* 2010; 37:2064–70. [PubMed: 20634241]
33. Jorge AJ, Freire MD, Ribeiro ML, et al. Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction (in Portuguese). *Rev Port Cardiol.* 2013; 32:647–52. [PubMed: 23910641]
34. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. *Circulation.* 2003; 108:13–6. [PubMed: 12821537]

35. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, et al. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. *Mayo Clin Proc.* 2011; 86:210–8. [PubMed: 21364112]
36. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. *Eur J Heart Fail.* 2008; 10:824–39. [PubMed: 18760965]
37. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. *Circulation.* 2002; 106:416–22. [PubMed: 12135939]
38. Carr BG, Dean AJ, Everett WW, et al. Intensivist bedside ultrasound (INBU) for volume assessment in the intensive care unit: a pilot study. *J Trauma.* 2007; 63:495–500. [PubMed: 18073592]
39. Kimura BJ, Dalugdugan R, Gilcrease GW 3rd, Phan JN, Showalter BK, Wolfson T. The effect of breathing manner on inferior vena caval diameter. *Eur J Echocardiog.* 2011; 12:120–3.
40. Dean, A.; Stahmer, S. Ultrasonography and emergency cardiac care. In: Field, JM., editor. *The Textbook of Emergency Cardiovascular Care and CPR.* New York, NY: Wolters Kluwer; 2009. p. 129-48.
41. Agricola E, Bove T, Oppizzi M, et al. “Ultrasound comet-tail images”: a marker of pulmonary edema: a comparative study with wedge pressure and extravascular lung water. *Chest.* 2005; 127:1690–5. [PubMed: 15888847]
42. Liteplo AS, Marill KA, Villen T, et al. Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. *Acad Emerg Med.* 2009; 16:201–10. [PubMed: 19183402]
43. Lichtenstein DA, Meziere GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. *Chest.* 2008; 134:117–25. [PubMed: 18403664]
44. Volpicelli G, Mussa A, Garofalo G, et al. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. *Am J Emerg Med.* 2006; 24:689–96. [PubMed: 16984837]
45. Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby JJ. Comparative diagnostic performances of auscultation, chest radiography, and lung ultrasonography in acute respiratory distress syndrome. *Anesthesiology.* 2004; 100:9–15. [PubMed: 14695718]
46. Maines M, Catanzariti D, Angheben C, Valsecchi S, Comisso J, Vergara G. Intrathoracic impedance and ultrasound lung comets in heart failure deterioration monitoring. *Pacing Clin Electrophysiol.* 2011; 34:968–74. [PubMed: 21477028]
47. Mullens W, Oliveira LP, Verga T, Wilkoff BL, Wilson Tang WH. Insights from internet-based remote intrathoracic impedance monitoring as part of a heart failure disease management program. *Congest Heart Fail.* 2010; 16:159–63. [PubMed: 20662868]
48. Shochat M, Charach G, Meyler S, et al. Internal thoracic impedance monitoring: a novel method for the preclinical detection of acute heart failure. *Cardiovasc Revasc Med.* 2006; 7:41–5. [PubMed: 16513522]
49. Hirschl MM, Kittler H, Woisetschlager C, et al. Simultaneous comparison of thoracic bioimpedance and arterial pulse waveform-derived cardiac output with thermodilution measurement. *Crit Care Med.* 2000; 28:1798–802. [PubMed: 10890622]
50. Piccoli A, Codognotto M, Cianci V, et al. Differentiation of cardiac and noncardiac dyspnea using bioelectrical impedance vector analysis (BIVA). *J Card Fail.* 2012; 18:226–32. [PubMed: 22385943]
51. Schlendorf KH, Russell SD. New diagnostic devices in heart failure. *Curr Opin Cardiol.* 2010; 25:262–7. [PubMed: 20308889]
52. Neuenschwander JF, Hiestand BC, Peacock WF, et al. A pilot study of implantable cardiac device interrogation by emergency department personnel. *Crit Pathways Cardiol.* 2014; 13:6–8.
53. Nowak RM, DiSomma S, Nanayakkara P, et al. The noninvasive hemodynamic phenotyping of patients presenting to the emergency department with acute heart failure: prognostic and therapeutic implications [abstract]. *Acad Emerg Med.* 2014; 21:S269–70.

54. Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. *J Card Fail.* 2013; 19:371–89. [PubMed: 23743486]
55. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med.* 2011; 364:797–805. [PubMed: 21366472]
56. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. *Lancet.* 2013; 381:29–39. [PubMed: 23141816]
57. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med.* 2012; 367:2296–304. [PubMed: 23131078]
58. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail.* 2012; 14:803–69. [PubMed: 22828712]
59. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J. Noninvasive ventilation in acute cardiogenic pulmonary edema. *N Engl J Med.* 2008; 359:142–51. [PubMed: 18614781]
60. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med.* 2011; 365:32–43. [PubMed: 21732835]
61. Ramirez A, Abelmann WH. Cardiac decompensation. *N Engl J Med.* 1974; 290:499–501. [PubMed: 4589873]
62. Gheorghide M, Braunwald E. A proposed model for initial assessment and management of acute heart failure syndromes. *JAMA.* 2011; 305:1702–3. [PubMed: 21521852]
63. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). *Am Heart J.* 2014; 167:529–36. [PubMed: 24655702]
64. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM. The pathophysiology of acute heart failure--is it all about fluid accumulation? *Am Heart J.* 2008; 155:9–18. [PubMed: 18082483]
65. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghide M. Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. *Eur J Heart Fail.* 2008; 10:165–9. [PubMed: 18279771]
66. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. *Ann Emerg Med.* 2007; 50:144–52. [PubMed: 17509731]
67. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. *Lancet.* 1998; 351:389–93. [PubMed: 9482291]
68. Gheorghide M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *JAMA.* 2006; 296:2217–26. [PubMed: 17090768]
69. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J.* 2005; 149:209–16. [PubMed: 15846257]
70. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. *Circ Heart Fail.* 2011; 4:669–75. [PubMed: 21934091]
71. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J.* 2007; 154:260–6. [PubMed: 17643574]
72. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation.* 2007; 116:1482–7. [PubMed: 17724259]

73. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. *JAMA*. 2002; 287:1541–7. [PubMed: 11911756]
74. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA*. 2007; 297:1319–31. [PubMed: 17384437]
75. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. *JAMA*. 2004; 291:1963–71. [PubMed: 15113814]
76. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. *JAMA*. 2007; 297:1883–91. [PubMed: 17473298]
77. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA*. 2013; 309:1125–35. [PubMed: 23478743]
78. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. *N Engl J Med*. 2010; 363:1419–28. [PubMed: 20925544]
79. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *JAMA*. 2007; 298:2009–19. [PubMed: 17986694]
80. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. *Cochrane Database Syst Rev*. 2013; 8:CD005151. [PubMed: 23922186]
81. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. *JAMA*. 2013; 310:2533–43.
82. Schuur JD, Venkatesh AK. The growing role of emergency departments in hospital admissions. *N Engl J Med*. 2012; 367:391–3. [PubMed: 22784039]
83. National Center for Health Statistics. Health, United States. 2012 With Special Feature on Emergency Care. Hyattsville, MD: U.S. Government Printing Office; 2013.
84. McCausland JB, Machi MS, Yealy DM. Emergency physicians' risk attitudes in acute decompensated heart failure patients. *Acad Emerg Med*. 2010; 17:108–10. [PubMed: 20078443]
85. Collins SP, Storrow AB. Moving toward comprehensive acute heart failure risk assessment in the emergency department: the importance of self-care and shared decision making. *JACC Heart Fail*. 2013; 1:273–80. [PubMed: 24159563]
86. Ezekowitz JA, Bakal JA, Kaul P, Westerhout CM, Armstrong PW. Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. *Eur J Heart Fail*. 2008; 10:308–14. [PubMed: 18280788]
87. Lee DS, Schull MJ, Alter DA, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. *Circ Heart Fail*. 2010; 3:228–35. [PubMed: 20107191]
88. Lee DS, Stitt A, Austin PC, et al. Prediction of heart failure mortality in emergent care: a cohort study. *Ann Intern Med*. 2012; 156:767–75. [PubMed: 22665814]
89. Pang PS, Jesse R, Collins SP, Maisel A. Patients with acute heart failure in the emergency department: do they all need to be admitted? *J Card Fail*. 2012; 18:900–3. [PubMed: 23207077]
90. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. *Circulation*. 2010; 122:1975–96. [PubMed: 20937981]
91. Peacock WF 4, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. *N Engl J Med*. 2008; 358:2117–26. [PubMed: 18480204]
92. Collins SP, Lindsell CJ, Jenkins CA, et al. Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies. *Am Heart J*. 2012; 164:825–34. [PubMed: 23194482]
93. Collins SP, Storrow AB. Acute heart failure risk stratification: can we define low risk? *Heart Fail Clin*. 2009; 5:75–83. vii. [PubMed: 19026388]

94. Butler J, Hanumanthu S, Chomsky D, Wilson JR. Frequency of low-risk hospital admissions for heart failure. *Am J Cardiol.* 1998; 81:41–4. [PubMed: 9462604]
95. Collins SP, Lindsell CJ, Naftilan AJ, et al. Low-risk acute heart failure patients: external validation of the Society of Chest Pain Center's recommendations. *Crit Pathw Cardiol.* 2009; 8:99–103. [PubMed: 19726928]
96. Collins SP, Peacock WF, Lindsell CJ, et al. S3 detection as a diagnostic and prognostic aid in emergency department patients with acute dyspnea. *Ann Emerg Med.* 2009; 53:748–57. [PubMed: 19232777]
97. Diercks DB, Peacock WF, Kirk JD, Weber JE. ED patients with heart failure: identification of an observational unit-appropriate cohort. *Am J Emerg Med.* 2006; 24:319–24. [PubMed: 16635705]
98. Peacock WF, Fonarow GC, Ander DS, et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. *Critical Pathw Cardiol.* 2008; 7:83–6.
99. Auble TE, Hsieh M, Gardner W, et al. A prediction rule to identify low-risk patients with heart failure. *Acad Emerg Med.* 2005; 12:514–21. [PubMed: 15930402]
100. Auble TE, Hsieh M, McCausland JB, Yealy DM. Comparison of four clinical prediction rules for estimating risk in heart failure. *Ann Emerg Med.* 2007; 50:127–35. [PubMed: 17449141]
101. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. *J Am Coll Cardiol.* 2013; 61:196–206. [PubMed: 23273292]
102. McKesson Corp. [Accessed Oct 3, 2014] InterQual Actionable Evidence-Based Criteria Portfolio. Available at: <http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCAQFjAA&url=http%3A%2F%2Fwww.mckesson.com%2Fdocuments%2Fpayers%2Finterqual-criteria%2F&ei=s-MuVLTeKI3saMjbgAG&usg=AFQjCNFDpQwjPYF5o74M4k400BcH-1pTmw&sig2=wDNIMqubHsV-X45-902SsQ&bvm=bv.76802529,d.d2s&cad=rja>
103. MCG Health, LLC. [Accessed Oct 3, 2014] Indicia for Utilization Review. Available at: <http://www.careguidelines.com/>
104. Wang H, Robinson RD, Coppola M, et al. The accuracy of interqual criteria in determining the need for observation versus hospitalization in emergency department patients with chronic heart failure. *Critical Pathw Cardiol.* 2013; 12:192–6.
105. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA.* 2010; 303:1716–22. [PubMed: 20442387]
106. Lee DS, Stukel TA, Austin PC, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. *Circulation.* 2010; 122:1806–14. [PubMed: 20956211]
107. Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart failure. *Cochrane Database Syst Rev.* 2012; 9:CD002752. [PubMed: 22972058]
108. Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. *Nurs Clin North Am.* 2008; 43:133–53. vii–viii. [PubMed: 18249229]
109. van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and possible solutions. *Int J Cardiol.* 2008; 125:203–8. [PubMed: 18031843]
110. Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. *BMC Cardiovas Disorders.* 2006; 6:43.
111. Barnason S, Zimmerman L, Young L. An integrative review of interventions promoting self-care of patients with heart failure. *J Clin Nurs.* 2012; 21:448–75. [PubMed: 22098479]
112. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol.* 2004; 44:810–9. [PubMed: 15312864]

113. Riegel B, Carlson B. Facilitators and barriers to heart failure self-care. *Patient Educ Couns*. 2002; 46:287–95. [PubMed: 11932128]
114. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. *Circulation*. 2009; 120:1141–63. [PubMed: 19720935]
115. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. *J Am Coll Cardiol*. 2007; 50:768–77. [PubMed: 17707182]
116. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. *J Am Coll Cardiol*. 2006; 47:76–84. [PubMed: 16386668]
117. Sheehy AM, Graf B, Gangireddy S, et al. Hospitalized but not admitted: characteristics of patients with “observation status” at an academic medical center. *JAMA Intern Med*. 2013; 173:1991–8. [PubMed: 23835927]
118. Wiler JL, Ross MA, Ginde AA. National study of emergency department observation services. *Acad Emerg Med*. 2011; 18:959–65. [PubMed: 21883638]
119. Somekh NN, Rachko M, Husk G, Friedmann P, Bergmann SR. Differences in diagnostic evaluation and clinical outcomes in the care of patients with chest pain based on admitting service: the benefits of a dedicated chest pain unit. *J Nucl Cardiol*. 2008; 15:186–92. [PubMed: 18371589]
120. Leykum LK, Huerta V, Mortensen E. Implementation of a hospitalist-run observation unit and impact on length of stay (LOS): a brief report. *J Hosp Med*. 2010; 5:E2–5. [PubMed: 20717893]
121. Lucas BP, Kumapley R, Mba B, et al. A hospitalist-run short-stay unit: features that predict length-of-stay and eventual admission to traditional inpatient services. *J Hosp Med*. 2009; 4:276–84. [PubMed: 19504489]
122. Schragger J, Wheatley M, Georgiopolou V, et al. Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. *Acad Emerg Med*. 2013; 20:554–61. [PubMed: 23758301]
123. Storrow AB, Collins SP, Lyons MS, Wagoner LE, Gibler WB, Lindsell CJ. Emergency department observation of heart failure: preliminary analysis of safety and cost. *Congest Heart Fail*. 2005; 11:68–72. [PubMed: 15860971]
124. Peacock WF, Fonarow GC, Ander DS, et al. Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1–6. *Acute Card Care*. 2009; 11:3–42. [PubMed: 19396642]
125. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. *Lancet*. 2009; 373:1429–39. [PubMed: 19329178]
126. Ezekowitz JA, Hernandez AF, O’Connor CM, et al. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. *J Am Coll Cardiol*. 2012; 59:1441–8. [PubMed: 22497823]
127. Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. *Eur Heart J*. 2009; 30:2233–40. [PubMed: 19561338]
128. Metra M, O’Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. *Eur Heart J*. 2011; 32:1519–34. [PubMed: 21388992]
129. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. *Eur J Heart Fail*. 2010; 12:1130–9. [PubMed: 20732868]
130. Pang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. *Eur Heart J*. 2008; 29:816–24. [PubMed: 18310669]

131. Redfield M, Butler J, O'Connor CM, et al. Reliable Evaluation of Dyspnea in the ROSE AHF trial (RED ROSE). *J Am Coll Cardiol*. 2014; 63(12 Suppl):10.1016/S0735-1097(14)60751-8
132. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol*. 2014; 63:747–62. [PubMed: 24291279]
133. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet*. 2011; 377:658–66. [PubMed: 21315441]
134. Sharma GV, Woods PA, Lindsey N, et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. *J Card Fail*. 2011; 17:718–25. [PubMed: 21872140]
135. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. *J Am Coll Cardiol*. 2004; 44:1328–33. [PubMed: 15364340]
136. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Am J Kidney Dis*. 2003; 41:571–9. [PubMed: 12612980]
137. Sanford SD, Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ. The influence of age, gender, ethnicity, and insomnia on Epworth sleepiness scores: A normative US population. *Sleep Med*. 2006; 7:319–26. [PubMed: 16713340]
138. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. *Arch Intern Med*. 2004; 164:2247–52. [PubMed: 15534162]
139. Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kurabayashi M. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. *Int Heart J*. 2010; 51:343–7. [PubMed: 20966607]
140. Logeart D, Lecuyer L, Thabut G, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. *Intensive Care Med*. 2007; 33:286–92. [PubMed: 17165016]
141. Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with in-hospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. *Am Heart J*. 2013; 166:1063–71. e3. [PubMed: 24268222]
142. Krim SR, Vivo RP, Krim NR, et al. Racial/ethnic differences in B-type natriuretic Peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from get with the guidelines-heart failure. *JACC Heart Fail*. 2013; 1:345–52. [PubMed: 24621938]
143. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. *J Am Coll Cardiol*. 2006; 47:91–7. [PubMed: 16386670]
144. Hess G, Runkel S, Zdunek D, Hitzler WE. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. *Clin Lab*. 2005; 51:167–72. [PubMed: 15819172]
145. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. *Eur Heart J*. 2006; 27:330–7. [PubMed: 16293638]
146. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. *Arch Intern Med*. 2007; 167:400–7. [PubMed: 17325303]
147. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. *Circulation*. 2005; 112:2163–8. [PubMed: 16203929]

148. Henzler T, Roeger S, Meyer M, et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. *Eur Respir J*. 2012; 39:919–26. [PubMed: 21965223]
149. Li ZF, Zhou DX, Wang QB, Pan WZ, Zhang L, Ge JB. Plasma N-terminal pro-brain natriuretic peptide levels are positively correlated with pulmonary arterial pressure in atrial septal defect patients. *Regul Pept*. 2013; 183C:13–6. [PubMed: 23499807]
150. Chi SY, Kim EY, Ban HJ, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. *Lung*. 2012; 190:271–6. [PubMed: 22246552]
151. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol*. 2011; 108:1645–50. [PubMed: 21890089]
152. Curiati MN, Silvestre OM, Pires LJ, et al. Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables. *Einstein (Sao Paulo)*. 2013; 11:273–7. [PubMed: 24136751]
153. Choi EY, Bahrami H, Wu CO, et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. *Circ Heart Fail*. 2012; 5:727–34. [PubMed: 23032197]
154. Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. *J Card Fail*. 2006; 12:452–7. [PubMed: 16911912]
155. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. *Int J Cardiol*. 2013; 168:2186–94. [PubMed: 23538053]
156. Stiell IG, Clement CM, Brison RJ, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. *Acad Emerg Med*. 2013; 20:17–26. [PubMed: 23570474]
157. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With The Guidelines Program. *Circ Cardiovasc Qual Outcomes*. 2010; 3:25–32. [PubMed: 20123668]
158. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. *Arch Intern Med*. 2008; 168:847–54. [PubMed: 18443260]
159. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *J Am Coll Cardiol*. 2008; 52:347–56. [PubMed: 18652942]
160. Rohde LE, Goldraich L, Polanczyk CA, et al. A simple clinically based predictive rule for heart failure in-hospital mortality. *J Card Fail*. 2006; 12:587–93. [PubMed: 17045176]
161. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005; 293:572–80. [PubMed: 15687312]




Figure 1.

A conceptual model of acute heart failure risk stratification in the ED based on known predictors of risk for mortality or serious adverse events, presence of absence of comorbidities, and self-care issues. Such an algorithm may augment clinical judgment in disposition decisions. ICU = intensive care unit.

Table 1

Summary of Diagnostic Accuracy of Findings on Chest Radiograph and Electrocardiogram for AHF in ED Patients Presenting With Dyspnea

Finding	Pooled		Summary LR (95% CI)	
	Sensitivity	Specificity	Positive	Negative
Chest radiograph				
Pulmonary venous congestion	0.54	0.96	12.0 (6.8–21.0)	0.48 (0.28–0.83)
Interstitial edema	0.34	0.97	12.0 (5.2–27.0)	0.68 (0.54–0.85)
Alveolar edema	0.06	0.99	6.0 (2.2–16.0)	0.95 (0.93–0.97)
Cardiomegaly	0.74	0.78	3.3 (2.4–4.7)	0.33 (0.23–0.48)
Pleural effusion	0.26	0.92	3.2 (2.4–4.3)	0.81 (0.77–0.85)
Any edema	0.70	0.77	3.1 (0.60–16.0)	0.38 (0.11–1.3)
Pneumonia	0.04	0.92	0.50 (0.29–0.87)	1.0 (1.0–1.1)
Hyperinflation	0.03	0.92	0.38 (0.20–0.69)	1.1 (1.0–1.1)
Electrocardiogram				
Atrial fibrillation	0.26	0.93	3.8 (1.7–8.8)	0.79 (0.65–0.96)
New T-wave changes	0.24	0.92	3.0 (1.7–5.3)	0.83 (0.74–0.92)
Any abnormal finding	0.50	0.78	2.2 (1.6–3.1)	0.64 (0.47–0.88)
ST elevation	0.05	0.97	1.8 (0.80–4.0)	0.96 (0.95–1.0)
ST depression	0.11	0.94	1.7 (0.97–2.9)	0.95 (0.90–1.0)

AHF = acute heart failure; LR = likelihood ratio.

Adapted from: Wang CS, Fitzgerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive HF? JAMA 2005;294:1944–56.¹³

Table 2

Factors Affecting Natriuretic Peptide Levels

	Renal Insufficiency	Age	BMI	Pulmonary Embolism/Pulmonary Hypertension	Ejection Fraction	Female Gender	Nonwhite Race
BNP	↑↑136	↑29	↓137,138	↑139,140	↓141	- Or ↑29,141	↓Or - Or ↑29,142
NT-proBNP	↑↑143	↑↑144,145	↓146,147	↑148-151	↓152	- Or ↑144	↓153,154

BMI = body mass index; BNP = B-type natriuretic peptide.

Table 3

Synopsis of Recommended AHF Therapies Based on ESC, HFSA and ACCF/AHA, and CCS Guidelines

Recommendation	ESC	HFSA	ACCF/AHA	CCS
Diuretic use				
AHF patients with fluid overload should receive diuretics	I/B	B	I/B	SR/MQ
Dosing	IV, to symptom improvement, consider high-dose regimen, NSR.	IV, titrate to symptom relief, minimize AE (C)	Initial IV dose should equal or exceed oral daily dose, then adjust based on response (I/B)	We recommend a loop diuretic, such as furosemide, for most patients with HF and congestive symptoms. When acute congestion is cleared, the lowest dose should be used that is compatible with stable signs and symptoms (SR/LQ).
Inadequate diuresis	Consider doubling loop diuretic (NSR) Consider adding thiazide Consider dopamine @ 2.5 µg/kg/min (NSR)	Increase dose (C) Continuous infusion (C) Add thiazide (C)	Add thiazide (IIa/B) Increase loop dose (IIa/B) Consider renal dose dopamine (IIb/B)	Increases in loop diuretics, cautious addition of a second diuretic (a thiazide or low-dose metolazone) (WR/MQ).
Ultrafiltration	Consider in refractory cases (NSR)	Refractory cases (C) In lieu of diuretics—selected patients (C)	In refractory cases of overload (IIb/B) Pulmonary congestion (IIb/C)	Patients with persistent congestion despite diuretic therapy, with or without impaired renal function, may, under experienced supervision, receive continuous venovenous ultrafiltration. (Practical tip)
Vasodilators, other pharmacologic therapy				Titrated to SBP > 100 mm Hg, for relief of dyspnea in hemodynamically stable patients (SBP > 100 mm Hg)
Nitrates	In pulmonary congestion and SBP > 110 mm Hg (IIa/B) caution in aortic/mitral stenosis	+ diuretic and no hypotension (B)	+ diuretic therapy (IIb/A)	SR/MQ
Nesiritide	NSR	After first-line therapy(C)	+ diuretic therapy (IIb/A)	WR/HQ
Vasopressin antagonist	NSR	NSR	Severe volume overload and Na < 135 (IIb/B)	Symptomatic or severe hyponatremia (<130 mmol/L) and persistent congestion despite standard therapy, to correct hyponatremia and the related symptoms (WR/MQ)
Opiates +/- antiemetic	IIa/C	NSR	NSR	NSR
Fluid restriction	NSR	<2 L/days if Na < 130 mEq/L; stricter if <125 mEq/L (C)	1.5–2 L/day especially in Na < 135 and congestion (IIa/C)	NSR
Thromboembolism prophylaxis	I/A	If no contraindication (B)	UFH, LMWH (I/B)	NSR

Recommendation	ESC	HFSA	ACCF/AHA	CCS
Respiratory support				
Oxygen	If SaO ₂ < 90% (I/C)	If hypoxia (C)	NSR	If hypoxia, titrated to an SaO ₂ > 90% (SR/MQ)
NIV	For RR > 20, caution in SBP < 85 mm Hg (IIa/B)	In severe dyspnea (A)	NSR	We recommend CPAP or BiPAP not be used routinely (SR/MQ)
Inotropic support	SBP < 85 mm Hg or hypoperfusion (IIa/C)	In selected hypotensive patient (C)	In short-term support of selected patients (IIb/B)	We recommend hemodynamically stable patients do not routinely receive inotropes like dobutamine, dopamine, or milrinone (SR/HQ).

ACCF/AHA = American College of Cardiology Foundation/American Heart Association; AHF = acute heart failure; BiPAP = bilevel positive airway pressure; CCS = Canadian Cardiovascular Society; CPAP = continuous positive airway pressure; ESC = European Society of Cardiology; HFSA = Heart Failure Society of America; NIV = noninvasive ventilation; NSR = no specific recommendation; SR/HQ = strong recommendation, high-quality evidence; SR/LQ = strong recommendation, low-quality evidence; SR/MQ = strong recommendation, moderate-quality evidence; WR/HQ = weak recommendation, high-quality evidence; WR/MQ = weak recommendation, moderate-quality evidence.

Table 4

Randomized Diagnostic and Phase III Therapeutic AHF Studies Over the Past 10 Years

Study/Author	Year/Sample Size	Primary Endpoint	Findings	Limitations
Diagnostic studies				
BASEL, Mueller	2004 (n = 452)	Time to discharge and cost of treatment	Time to discharge and costs of treatment were reduced in patients with undifferentiated dyspnea who were randomized to rapid, bedside BNP testing.	Conducted in Europe, median LOS and health care systems much different than United States.
IMPROVE-CHF, Moe	2007 (n = 500)	ED LOS and total direct medical costs of treatment	ED LOS and cost of treatment were reduced with addition of NT-proBNP to clinical gestalt for patients with undifferentiated dyspnea.	Conducted in Canada, which has different health care cost structure than United States.
REDHOT II, Singer	2009 (n = 447)	Hospital LOS	No statistical difference in length of stay with serial BNP testing.	Convenience sample; potentially underpowered.
Therapeutic studies				
SURVIVE, Mebazaa	2007 (n = 1327)	All-cause mortality at 180 days	No difference in mortality in patients requiring inotrope therapy with randomization to levosimendan or dobutamine.	Conducted in Europe with a drug (levosimendan) that was never FDA approved in the United States. Bolus hypotension may have been a significant contributor to adverse events.
EVEREST, Gheorghiade	2007 (n = 4133)	Composite of global clinical status and body weight on day 7	Compared to placebo tolvaptan had significantly greater improvement in the composite.	The composite endpoint was largely driven by changes in body weight.
VERITAS, McMurray	2007 (n = 1435)	Change in dyspnea over 24 hours and incidence of death or WHF on day 7	No significant difference in dyspnea or death/WHF between tezoseptan and standard therapy.	
3CPO, Gray	2008 (n = 1069)	Death or intubation within 7 days	No difference in mortality with NIPPV versus standard oxygen therapy or either endpoint with use of CPAP versus BiPAP.	Open-label study with extensive crossover to NIPPV in patients randomized to standard oxygen therapy.
PROTECT, Massie	2010 (n = 2033)	Overall treatment success defined as early dyspnea improvement and no death, HF readmission, or WRF	No significant difference between rolofylline and placebo.	
ASCEND, O'Connor	2011 (n = 7141)	Dyspnea and rehospitalization/death within 30 days	Prespecified dyspnea endpoint not met; no differences in death between nesiritide and standard care.	Patients enrolled long after ED stay; significantly greater proportion with hypotension in nesiritide group.
DOSE-AHF, Felker	2011 (n = 308)	Dyspnea and WRF at 72 hours	No significant difference between bolus/drip or high-/low-dose furosemide.	Patients randomized up to 24 hours after ED presentation; population largely white males with low EF; not powered for longer-term outcomes.
RELAX-AHF-1, Teerlink	2013 (n = 1161)	Improvement in dyspnea measured by both Likert and VAS on day 5	Significant improvement in VAS by serelaxin compared to placebo.	No difference in Likert between serelaxin and placebo; clinical meaning of VAS difference unclear.

Study/Author	Year/Sample Size	Primary Endpoint	Findings	Limitations
ROSE-AHF, Chen	2013 (<i>n</i> = 360)	72-hour urine volume and change in cystatin C	No difference between low-dose dopamine and low-dose nesiritide compared to placebo in either endpoint.	Not powered for longer-term outcomes.
REVIVE II, Packer	2013 (<i>n</i> = 600)	Clinical composite of "improved," "unchanged," or "worse" at 6 hr, 24 hr, and 5 days	More improvement in levosimendan-treated patients with less worsening. However, more hypotension and arrhythmias were observed with a numerically higher number of deaths.	Bolus hypotension may have been a significant contributor to adverse events.
PRONTO, Peacock	2014 (<i>n</i> = 104)	Targeted BP control in first 30 minutes of IV vasodilator	Clevidipine provided more rapid BP control compared to standard therapy.	Open-label study; more BP overshoot in clevidipine arm; efficacy was monitored only to 12 hours; not powered for longer-term outcomes

BiPAP = bilevel positive airway pressure; BP = blood pressure; CPAP = continuous positive airway pressure; EF = ejection fraction; IV = intravenous; LOS = length of stay; NIPPV = noninvasive positive pressure ventilation; VAS = visual analog scale; WHF = worsening heart failure; WRF = worsening renal function.

Table 5

Associated Clinical Characteristics and Treatment Approaches Based on ED Presentation Phenotype

ED Presentation Phenotype	Clinical Characteristics	Treatment
Low BP (SBP < 100 mm Hg)	Known/suspected low LVEF	Diuretics (+++)
		Inotropes/Pressors (++)
		Mechanical support (+)
Normal BP (SBP 100–140 mm Hg)	Subacute systems	Diuretics (++)
	Preserved or reduced LVEF	IV vasodilators (+)
	Dietary/medication indiscretion	Topical nitrates (++)
High BP (SBP > 140 mm Hg)	History of HTN	Topical/SL nitrates (++)
	Abrupt system onset	Diuretics (+)
	Flash pulmonary edema	IV vasodilators (+++)
	Multiple non-CV comorbidities	NIV

+ = Relative intensity of use; BP = blood pressure; CAD = coronary artery disease; CRI = chronic renal insufficiency; CV = cardiovascular; HTN = hypertension; IV = intravenous; LVEF = left ventricle ejection fraction; NIV = NIV = noninvasive ventilation; SBP = systolic blood pressure; SL = sublingual.

Table 6

Selected and Recent AHF Risk Stratification Studies Determining Events Within 30 Days or Less of Index ED Presentation

First Author Year	Study Type*	N	Predicted Outcome	Variables in Final Model
Lassus ¹⁵⁵ 2013	I, P	441–4,450 (pooled analysis, total <i>n</i> varied by biomarker evaluated)	30-day and 1-year mortality	ST2, MR-proADM, CRP, NT-proBNP, BNP, MR-proANP in addition to clinical model (age, gender, blood pressure on admission, estimated glomerular filtration rate < 60 mL/min/1.73 m ² , sodium and hemoglobin levels, and heart rate)
Stiell ¹⁵⁶ 2013	E, P	559	30-day death and 14-day serious nonfatal events	h/o TIA/CVA, vital signs, ECG, and laboratory findings
Lee ⁸⁸ 2012	E, R	12,591	7-day mortality	HR, creatinine, BP, O ₂ sat, Tn, cancer, home metolazone, EMS transport
Peterson ¹⁵⁷ 2010	I, R	39,783	In-hospital mortality	Age, SBP, BUN, HR, Na, COPD, nonblack race
Fonarow ¹⁵⁸ 2008	I, R	5,791	In-hospital mortality, 60- to 90-day mortality or rehospitalization	Pneumonia, cardiac ischemia, worsening renal function
Hsieh ¹⁰ 2008	I, R	8,384	Inpatient mortality or serious medical complications, 30-day mortality	pH, pulse, renal function, WBC, glucose, sodium
Abraham ¹⁵⁹ 2008	I, R	48,612	In-hospital mortality	Age, HR, SBP, Na, creatinine, HF as primary cause for admission, LVSD
Rohde ¹⁶⁰ 2006	I, P	779	In-hospital mortality	Cancer, SBP, creatinine, BUN, Na, age
Diercks ⁹⁷ 2006	E, P	499	Stay < 24 hours in observation and no 30-day adverse cardiac events	Tn, SBP
Auble ⁹⁹ 2005	R	33,533	Inpatient mortality or serious medical complications, 30-day mortality, and AHF readmission	pH, pulse, renal function, WBC, glucose, sodium
Fonarow ¹⁶¹ 2005	I, R	65,275	In-hospital mortality	BUN, SBP, creatinine

* I = inpatient, E = emergency department patients, R = retrospective, P = prospective

ANP = atrial natriuretic peptide; BNP = B-type natriuretic peptide; BP = blood pressure; BUN = blood urea nitrogen; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; CVA = cerebrovascular accident; HR = heart rate; LVSD = left ventricular systolic dysfunction; SBP = systolic blood pressure; TIA = transient ischemic attack; Tn = troponin; WBC = white blood cell count.

Table 7

Components of the Emergency HF Mortality Risk Grade (Calculation Available Online at www.annals.org)⁸⁸

• Age	• Creatinine
• Transported by EMS	• Potassium
• Systolic blood pressure	• Cardiac troponin
• Heart rate	• Active cancer
• Oxygen saturation (lowest initial/triage)	• Metolazone at home

HF = heart failure.

Table 8Recommendations for Appropriate Candidates for an Observation Unit Stay⁹⁸

	Clinical Features of Patients Considered for Observation Management	
	Recommended	Suggested
Blood pressure	SBP > 100 mm Hg	SBP > 120 mm Hg
Respiratory rate	<32 breaths/min	NR
Renal function	BUN < 40 mg/dL	NR
	Creatinine < 3.0 mg/dL	NR
ACS	No ischemic changes or elevated troponin	NR
Natriuretic peptides	NR	BNP < 1000; NT-proBNP < 5000

ACS = ••••••••; BNP = B-type natriuretic peptide; BUN = blood urea nitrogen; NR = no recommendation.